On Aug. 22, the FDA approved Oxervate, the first drug for the treatment of neurotrophic keratitis; it is produced by the Italian pharmaceutical company Dompé. Cenegermin was approved in the European Union as an eye drop formulation for the treatment of moderate to severe neurotrophic keratitis in adults in July 2017.
Oxervate (cenegermin) was studied for the treatment of moderate to severe neurotrophic keratitis in adults; it is the first biotechnological treatment authorized for this indication.
Neurotrophic keratitis is a fairly rare eye disease, affecting fewer than five in 10,000
Uncategorized